Jan 24, 2021
In this episode, we chat with Doug Drysdale, CEO of Cybin. Cybin, is a life sciences company advancing mushroom based psychedelic pharmaceuticals and non-psychedelic nutraceutical products as potential therapies for psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aimed at...
Jan 9, 2021
In this mental health market update episode, we are covering
valuation trends, investor sentiment, and our 9 key takeaways from
the mental health startup market heading into 2021.
We cover public and private market valuation trends impacting mental health startups, and we dig into results from a 150-investor survey we...